Biomarkers: A molecular approach to cancer epidemiology

Annals of the Academy of Medicine Singapore

Volumn 25, Issue 1, 1996, Pages 49-54

  Shi, C Y ^b   Seow, A ^a   Lin, Y ^a   Chia, K S ^a   Ong, C N ^a   Chan, S H ^b   Lee, H P ^a  

^a Dept of Comm Occup and Fam Med ^*

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Biological monitoring; Cancer aetiology; Genetic susceptibility; Oncogenes; Tumour suppressor genes

Indexed keywords

TUMOR MARKER;

EPIDEMIOLOGY; GENETICS; HUMAN; NEOPLASM; RESEARCH; REVIEW; SINGAPORE;

EPIDEMIOLOGY, MOLECULAR; HUMANS; NEOPLASMS; RESEARCH; SINGAPORE; TUMOR MARKERS, BIOLOGICAL;

EID: 0029691803     PISSN: 03044602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Higginson J. The role of the pathologist in environmental medicine and public health. Am J Pathol 1977; 86:459-84
2. Perera F P, Weinstein I B. Molecular epidemiology and carcinogen-DNA adduct detection: new approaches to studies of human cancer causation. J Chron Dis 1982; 35:581-600.
3. Hulka B S. Overview of biological markers. In: Hulka B S, Wilcosky T C, Griffith J D, editors. Biological Markers in Epidemiology. New York: Oxford Univ Press, 1990:3-15.
4. Willett W. Challenges for public health nutation in the 1990s. Am J Public Health 1990; 80:1295-8.
5. Shulte P A. A conceptual and historical framework for molecular epidemiology. In. Schulte P A, Perera F P, editors. Molecular Epidemiology: Principles and Practices San Diego: Academic Press Inc, 1993:3-44.
6. Weinstein I B. The origins of human cancer: molecular mechanisms of carcinogenesis and their implications for cancer prevention and treatment. Cancer Res 1988; 48:4135-43.
7. Neumann H-G. Analysis of haemoglobin as a dose monitor for alkylating and arylating agents Arch Toxicol 1984; 56:1-6
8. Randerath K, Randerath E, Agrawal H P, Reddy M V. Biochemical (postlabelling) methods for analysis of caranogen-DNA adducts. IARC Sci Publ 1984; 59:217-31.
9. 32P-postlabelling analysis of cigarette smoking-related DNA adducts in target tissues of human carcinogenesis. Proc Am Assoc Cancer Res 1987; 28:98.
10. 32P-postlabelling analysis. Carcinogenesis 1990; 11:205-11
11. 32P-postlabelling analysis of DNA adducts in monocytes of smokers and passive smokers. Int Arch Occup Environ Health 1990; 62:299-303.
12. Hemminki K, Grzybowska E, Chorazy M, Twardowska-Saucha K, Scroczynski J W, Putman K L, et al. DNA adducts in humans environmentally exposed to aromatic compounds in an industrial area of Poland. Carcinogenesis 1990; 11:1229-31.
13. Hemminki K, Randerath K, Reddy M V, Putman K L, Santella R M, Perera F P, et al. Postlabelling and immunoassay analysis of polycydic aromatic hydrocarbons-adducts of deoxyribonucleic acid in white blood cells of foundry workers. Scand J Work Environ Health 1990; 16:158-62
14. Perera F P, Hemminki K, Gryzbowska E, Motykiewicz G, Michalska J, Santella R M, et al. Molecular and genetic damage in humans from environmental pollution in Poland. Nature 1992; 360:256-8.
15. Hollstein M, Sidransky D, Vogelstein B, Harris C. p53 mutations in human cancers. Science 1991; 253:49-53.
16. Caron de Frommentel C, Soussi T. TP53 tumour suppressor gene: a model for investigating human mutagenesis. Genes Chromosom Cancer 1992; 4:1-15.
17. Harris CC, Hollstein M Clinical implications of the p53 tumour-suppressor gene. N Engl J Med 1993; 329:1318-27.
18. Debuire B, Paterlini P, Pontisso P, Basso G, May E. Analysis of the p53 gene in European hepatocellular carcinomas and hepatoblastomas. Oncogene 1993; 8-2303-6.
19. Bressac B, Kew M, Wands J, Ozturk M. Selective G to T mutaaons of p53 gene in hepatocellular carcinoma from southern Africa. Nature 1991; 350:429-31.
20. Hsu I C, Metcalf R A, Sun T, Welsh J A, Wang N J, Harris C C. Mutation hotspot in the p53 gene in human hepatocellular carcinomas Nature 1991; 350:427-8.
21. Scorsone K A, Zhou Y Z, Butel J S, Slagle B L. p53 mutations cluster at codon 249 in hepatitis B virus-positive hepatocellular carcinomas from China-Cancer Res 1992; 52:1635-8.
22. Aguilar F, Hussain S, Ceruth P. Aflafcoxin B1 induces the transversion of G→T in codon 249 of the p53 tumour suppressor gene in human hepatocytes. Proc Natl Acad Sci USA 1993; 90:8586-90.
23. Shi C Y, Phang T W, Lin Y, Wee A, Li B, Lee H P, et al. Codon 249 mutation of the p53 gene is a rare event in hepatocellular carcinomas from ethnic Chinese in Singapore. Br J Cancer 1995; 72:146-9.
24. Barbacid M. ras genes. Annu Rev Biochem 1987; 56:779-827.
25. Brandt-Rauf P W, Pinus M R. Oncogenes and oncogene products. Occup Med 1987; 2:27-38.
26. Smith D R, Elnatan J, Myint T, Goh H S. Association of activated protooncogene ras and myc in colorectal carcinomas. Ann Acad Med Singapore 1995, 24:393-8.
27. Phang T W, Shi C Y, Wee A, Ngoi S S, Li B, Lee H P, et al. K-ras mutation in colorectal carcinomas from Singapore. Int J Oncol 1995; 6:191-5.
28. Goh H S, Chan C S, Khine K, Smith D R. p53 and behaviour of colorectal cancer. Lancet 1994; 344:233-4.
29. Sun X F, Carstensen J M, Zhang H, Stal O, Wingren S, Hatschek T, et al. Prognostic significance of cytoplasmic p53 oncoprotein in colorectal adenocarcinoma. Lancet 1992, 340:1369-73.
30. Guengerich F P, Lieber D C. Enzymatic activation of chemicals to toxic metabolites. Crit Rev Toxicol 1985; 14:259-307.
31. Poulsen H E, Loft S, Wassermann K. Cancer risk related to genetic polymorphisms in carcinogen metabolism and DNA repair. Pharmacol Toxicol 1993; 72(Suppl 1):93-103.
32. Hein D W. Acetylator genotype and arylamine-induced carcinogenesis. Biochim Biophys Acta 1988; 948-37-66.
33. Clark D WJ. Genetically determined variability in acetylation and oxidation: therapeutic implications. Drugs 1985, 29:342-75
34. Hanke J, Krajewska B. Acerylation phenotype and bladder cancer. J Occup Med 1990; 32:917-8.
35. Yu M C, Skipper P L, Taghizadeh K, Tannenbaum S R, Chan K K, Henderson B E, et al. Acetylator phenotype, aminobiphenyl-haemoglobin adduct levels, and bladder cancer risk in White, Blacks, and Asian men in Los Angeles, California J Natl Cancer Inst 1994, 86:712-6.
36. Lee E J D, Zhao B, Moochhala S M, Ngoi S S. Frequency of mutant CYP1A1, NAT2and GSTM1 alleles in anormal Chinese population. Pharmacogenetics 1994; 4:355-8.
37. Zhao B, Lee E J D, Wong J Y Y, Yeoh P N, Gong N H. Frequency of mutant CYP1A1, NAT2 and GSTM1 alleles in normal Indians and Malays. Pharmacogenetics 1995; 5:275-80.
38. Chan S H, Day N E, Kunaratnam N, Chia K B, Simons M J. HLA and nasopharyngeal carcinoma in Chinese - a further study. Int J Cancer 1983; 32-171-6.
39. Chan SH, Tan CB, Lin YN, Wee GB, Degli-Esposti MA, Dawkins RL HLA and Singaporean Chinese with myasthenia gravis. Int Arch Allergy Immunol 1993, 101:119-25.
40. Chen Y, Chan SH. Polymorphism of T-cell receptor genes in nasopharyngeal carcinoma. Int J Cancer 1994; 56:830-3.
41. Perera F P, Jefferey A M, Brandt-Rauf P W. Molecular epidemiology and cancer prevention. Cancer Detect Prev 1990; 14:639-45.